Interaction of immune cells with renal cancer development : Mendelian randomization (MR) study
© 2024. The Author(s)..
BACKGROUND: Renal cell carcinoma (RCC) is a prevalent and extensively immune-infiltrated malignancy of the urinary system. Immune cells play a crucial role in both the progression and therapeutic interventions targeting RCC. Nevertheless, the interplay between RCC and immune cells remains understudied, lacking substantial evidence supporting their causal relationship.
METHODS: For the purpose of investigating the causal connection between RCC and immune cell characteristics, a two-way two-sample Mendelian randomization (MR) analysis was carried out in this study. The aim was to determine whether specific immune cell traits have a causal impact on the risk of RCC. In order to achieve this, publicly accessible genetic data was utilized to examine and establish the potential relationship between 731 immune cell characteristics and the likelihood of developing RCC. Additionally, various techniques were applied to verify the reliability, variability, and presence of horizontal pleiotropy in the outcomes.
RESULTS: We found a bidirectional causal relationship between RCC and immune cells according to the MR analysis results. It should be noted that CD4-CD8-T cells (OR = 1.61, 95%CI = 1.02-2.55, P = 4.07 × 10-2) pose a risk for RCC, whereas BAFF-R (OR = 0.69, 95%CI = 0.53-0.89, P = 5.74 × 10-3) and CD19 (OR = 0.59, 95%CI = 1.02-2.55, P = 4.07 × 10-2) on B cells act as protective factors. Furthermore, the presence of RCC reduces the levels of B cells (OR = 1.05, 95%CI = 1.01-1.09, P = 1.19 × 10-2) and CD8 + T cells (OR = 1.04, 95%CI = 1.00-1.08, P = 2.83 × 10-2).
CONCLUSIONS: Our research illustrates the intricate correlation between immune cells and RCC, presenting novel insights for the prospective safeguarding against RCC risk and the exploration of fresh therapeutic targets.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
BMC cancer - 24(2024), 1 vom: 09. Apr., Seite 439 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lu, Zhongwen [VerfasserIn] |
---|
Links: |
---|
Themen: |
Immune cells |
---|
Anmerkungen: |
Date Completed 11.04.2024 Date Revised 25.04.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12885-024-12196-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370839927 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370839927 | ||
003 | DE-627 | ||
005 | 20240425233658.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240410s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12885-024-12196-8 |2 doi | |
028 | 5 | 2 | |a pubmed24n1386.xml |
035 | |a (DE-627)NLM370839927 | ||
035 | |a (NLM)38594655 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lu, Zhongwen |e verfasserin |4 aut | |
245 | 1 | 0 | |a Interaction of immune cells with renal cancer development |b Mendelian randomization (MR) study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.04.2024 | ||
500 | |a Date Revised 25.04.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a BACKGROUND: Renal cell carcinoma (RCC) is a prevalent and extensively immune-infiltrated malignancy of the urinary system. Immune cells play a crucial role in both the progression and therapeutic interventions targeting RCC. Nevertheless, the interplay between RCC and immune cells remains understudied, lacking substantial evidence supporting their causal relationship | ||
520 | |a METHODS: For the purpose of investigating the causal connection between RCC and immune cell characteristics, a two-way two-sample Mendelian randomization (MR) analysis was carried out in this study. The aim was to determine whether specific immune cell traits have a causal impact on the risk of RCC. In order to achieve this, publicly accessible genetic data was utilized to examine and establish the potential relationship between 731 immune cell characteristics and the likelihood of developing RCC. Additionally, various techniques were applied to verify the reliability, variability, and presence of horizontal pleiotropy in the outcomes | ||
520 | |a RESULTS: We found a bidirectional causal relationship between RCC and immune cells according to the MR analysis results. It should be noted that CD4-CD8-T cells (OR = 1.61, 95%CI = 1.02-2.55, P = 4.07 × 10-2) pose a risk for RCC, whereas BAFF-R (OR = 0.69, 95%CI = 0.53-0.89, P = 5.74 × 10-3) and CD19 (OR = 0.59, 95%CI = 1.02-2.55, P = 4.07 × 10-2) on B cells act as protective factors. Furthermore, the presence of RCC reduces the levels of B cells (OR = 1.05, 95%CI = 1.01-1.09, P = 1.19 × 10-2) and CD8 + T cells (OR = 1.04, 95%CI = 1.00-1.08, P = 2.83 × 10-2) | ||
520 | |a CONCLUSIONS: Our research illustrates the intricate correlation between immune cells and RCC, presenting novel insights for the prospective safeguarding against RCC risk and the exploration of fresh therapeutic targets | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Immune cells | |
650 | 4 | |a Mendelian randomization | |
650 | 4 | |a RCC | |
650 | 4 | |a Tumor microenvironment | |
700 | 1 | |a Yin, Yu |e verfasserin |4 aut | |
700 | 1 | |a Rao, Tian |e verfasserin |4 aut | |
700 | 1 | |a Xu, Xinchi |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Kai |e verfasserin |4 aut | |
700 | 1 | |a Liu, Zhanpeng |e verfasserin |4 aut | |
700 | 1 | |a Qin, Chao |e verfasserin |4 aut | |
700 | 1 | |a Tang, Min |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 24(2024), 1 vom: 09. Apr., Seite 439 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:09 |g month:04 |g pages:439 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-024-12196-8 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2024 |e 1 |b 09 |c 04 |h 439 |